[1] |
CAO X, SONG L N, YANG J K. ACE2 and energy metabolism:the connection between COVID-19 and chronic metabolic disorders[J]. Clin Sci (Lond), 2021, 135(3):535-554.
|
[2] |
PRADA J A H, FERREIRA A J, KATOVICH M J, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents[J]. Hypertension, 2008, 51(5):1312-1317.
|
[3] |
GJYMISHKA A, KULEMINA L V, SHENOY V, et al. Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug[J]. FASEB J, 2010, 24(S1):1032.
|
[4] |
VERMA A, SHAN Z Y, LEI B, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy[J]. Mol Ther, 2012, 20(1):28-36.
|
[5] |
HABER P K, YE M H, WYSOCKI J, et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators:studies in vivo, ex vivo, and in vitro[J]. Hypertension, 2014, 63(4):774-782.
|
[6] |
张 许. 无机焦磷酸酶(PPA1)在脂肪细胞分化过程中的功能研究[D]. 南京:南京医科大学, 2015.ZHANG X. Functional study of inorganic pyrophosphatase (PPA1) during adipocyte differentiation[D]. Nanjing:Nanjing Medical University, 2015. (in Chinese)
|
[7] |
BRUCE E B, SAKARYA Y, KIRICHENKO N, et al. ACE2 activator diminazene aceturate reduces adiposity but preserves lean mass in young and old rats[J]. Exp Gerontol, 2018, 111:133-140.
|
[8] |
QI Y F, ZHANG J, COLE-JEFFREY C T, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology[J]. Hypertension, 2013, 62(4):746-752.
|
[9] |
VELKOSKA E, PATEL S K, GRIGGS K, et al. Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy[J]. PLoS One, 2015, 10(3):e0118758.
|
[10] |
TAO L F, QIU Y G, FU X Y, et al. Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-κB pathways in humanretinal pigment epithelium[J]. J Neuroinflammation, 2016, 13:35.
|
[11] |
COUTINHO D C O, MONNERAT-CAHLI G, FERREIRA A J, et al. Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats[J]. Europace, 2014, 16(11):1689-1696.
|
[12] |
HALES C M, CARROLL M D, FRYAR C D, et al. Prevalence of obesity among adults and youth:United States, 2015-2016[J]. NCHS Data Brief, 2017(288):1-8.
|
[13] |
EVANS C E, MINERS J S, PIVA G, et al. ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease[J]. Acta Neuropathol, 2020, 139(3):485-502.
|
[14] |
刘 颖. 血管紧张素转化酶2在非酒精性脂肪肝病中的保护作用及其机制[D]. 南京:南京农业大学, 2019.LIU Y. Protective effect and its mechanism of angiotensin converting enzyme 2 (ACE2) in nonalcoholic fatty liver disease (NAFLD)[D]. Nanjing:Nanjing Agricultural University, 2019. (in Chinese)
|
[15] |
DE MACEDO S M, GUIMARARES T A, ANDRADE J M O, et al. Angiotensin converting enzyme 2 activator (DIZE) modulates metabolic profiles in mice, decreasing lipogenesis[J]. Protein Pept Lett, 2015, 22(4):332-340.
|
[16] |
JOVIANO-SANTOS J V, SANTOS-MIRANDA A, JOCA H C, et al. Diminazene aceturate (DIZE) has cellular and in vivo antiarrhythmic effects[J]. Clin Exp Pharmacol Physiol, 2020, 47(2):213-219.
|
[17] |
LI S M, LI Y Q, XU H, et al. ACE2 attenuates epithelial-mesenchymal transition in MLE-12 cells induced by silica[J]. Drug Des Devel Ther, 2020, 14:1547-1559.
|
[18] |
RAJAPAKSHA I G, MAK K Y, HUANG P, et al. The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice[J]. Sci Rep, 2018, 8(1):10175.
|
[19] |
任万平, 邵 伟, 雒诚龙, 等. 外源性添加磷酸二羟基丙酮对小鼠脂肪细胞三酰甘油及关键代谢酶含量的影响[J]. 畜牧兽医学报, 2018, 49(7):1423-1431.REN W P, SHAO W, LUO C L, et al. Effects of exogenously added dihydroxyacetone phosphate on the contents of triglycerides and key metabolic enzymes in mouse adipocytes[J]. Acta Veterinaria et Zootechnica Sinica, 2018, 49(7):1423-1431. (in Chinese)
|
[20] |
李 姣, 胡 群, 罗 佩, 等. 肝脏脂质代谢关键转录因子研究进展[J]. 动物医学进展, 2016, 37(4):90-93.LI J, HU Q, LUO P, et al. Progress on key transcription factors in liver lipid metabolism[J]. Progress in Veterinary Medicine, 2016, 37(4):90-93. (in Chinese)
|
[21] |
CAO X, YANG F Y, XIN Z, et al. The ACE2/Ang-(1-7)/Mas axis can inhibit hepatic insulin resistance[J]. Mol Cell Endocrinol, 2014, 393(1-2):30-38.
|
[22] |
TAKEDA M, YAMAMOTO K, TAKEMURA Y, et al. Loss of ACE2 exaggerates high-calorie diet-induced insulin resistance by reduction of GLUT4 in mice[J]. Diabetes, 2013, 62(1):223-233.
|
[23] |
SANTOS S H S, FERNANDES L R, MARIO E G, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism[J]. Diabetes, 2008, 57(2):340-347.
|